

### H.2.1.2 Development of geographic atrophy (GA) in people due to AMD: risk outcomes for developing GA

#### Ocular risk factors

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
Cataract surgery								
Chew (2009) Prospective cohort	5,841	Very serious <sup>1,2</sup>	N/A	Not serious	Serious <sup>5</sup>	HR (95% CI)	Right eye: 0.80 (0.61, 1.06) Left eye: 0.95 (0.71, 1.26)	VERY LOW

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
Hyperpigmentation (none as reference category)								
CAPT (2008) Prospective cohort	1,052	Serious <sup>1</sup>	N/A	Not serious	Not serious	HR (95% CI)	<250 um: 2.82 (1.30, 6.12) >=250 um: 10.4 (4.51, 24.0)	MODERATE
Hyperpigmentation								
Klein (2007)	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	Increased pigment present vs absent: 15.8 (7.6, 32.8)	MODERATE
Retinal pigment epithelium depigmentation								
Klein (2007) Prospective cohort	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	RPE depigmentation present vs absent: 11.1 (5.0, 24.4)	MODERATE
Retinal pigment epithelium depigmentation								
CAPT (2008) Prospective cohort	1,052	Serious <sup>1</sup>	N/A	Not serious	Not serious	HR (95% CI)	2.64 (1.26, 5.53)	MODERATE
Pigmentary changes								
Finger (2014) Retrospective cohort	200	Very serious <sup>1,3,4</sup>	N/A	Not serious	Not serious	HR (95% CI)	Pigmentary Changes: 5.75 (2.09, 15.84)	LOW
Pigmentary abnormalities								
Klein (2007) Prospective	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	Pigmentary abnormalities present vs absent:	MODERATE

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
ve cohort							15.2 (7.3, 31.6)	
% of area covered by drusen (<10 as reference category)								
CAPT (2008) Prospective cohort	1,052	Serious <sup>1</sup>	N/A	Not serious	Not serious	HR (95% CI)	10-24%: 2.39 (1.44, 3.97) >=25%: 5.10 (2.57, 10.1)	MODERATE
Drusen area								
Klein (2007) Prospective cohort	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	Drusen area >16877 $\mu\text{m}^2$ vs $\leq 2596 \mu\text{m}^2$ : 24.0 (3.2, 179)	MODERATE
Large drusen								
Finger (2014) Retrospective cohort	200	Very serious <sup>1,3,4</sup>	N/A	Not serious	Not serious	HR (95% CI)	Drusen $\geq 125\mu\text{m}$ : 11.73 (1.47, 93.81)	LOW
Large drusen								
Klein (2007) Prospective cohort	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	Drusen > 125 $\mu\text{m}$ vs <63 $\mu\text{m}$ in diameter: 14.5 (5.9, 35.7)	MODERATE
Soft distinct drusen vs hard distinct drusen								
Klein (2007) Prospective cohort	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Very serious <sup>6</sup>	Time-adjusted odds ratios (95% CI)	1.2 (0.3, 5.7)	VERY LOW
Soft indistinct vs soft distinct drusen or hard distinct drusen								

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
Klein (2007) Prospective cohort	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	14.6 (6.8, 31.1)	MODERATE
Reticular drusen vs Soft distinct drusen								
Klein (2008) Prospective cohort	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	41.78 (9.43, 185.14)	MODERATE
Reticular drusen vs Soft indistinct drusen								
Klein (2008) Prospective cohort	3,917	Serious <sup>1,3</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	6.23 (1.70, 22.73)	MODERATE
Reticular pseudodrusen								
Finger (2014) Retrospective cohort	200	Very serious <sup>1,3,4</sup>	N/A	Not serious	Not serious	HR (95% CI)	Reticular pseudodrusen: 4.93 (1.06, 22.93)	LOW
Baseline visual acuity (20/25-20/40 as reference category)								
Grunwald (2014) Prospective cohort	1,024	Serious <sup>3</sup>	N/A	Not serious	Not serious	HR (95% CI)	20/50–20/80: 1.66 (1.14, 2.44) 20/100–20/160: 1.70 (1.10, 2.62) 20/200–20/320: 2.65 (1.43, 4.93)	LOW
Retinal angiomatous proliferation lesion								
Grunwald	1,024	Serious <sup>3</sup>	N/A	Not serious	Not serious	HR (95% CI)	1.69 (1.16, 2.47)	MODERATE

© NICE 2018. All rights reserved. See [Notice of rights](#).

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
(2014) Prospective cohort								
Geographic atrophy in fellow eye								
Grunwald (2014) Prospective cohort	1,024	Serious <sup>3</sup>	N/A	Not serious	Not serious	HR (95% CI)	2.07 (1.40, 3.08)	MODERATE
<ol style="list-style-type: none"> <li>Evidence of bias from study attrition (for example, the paper is not clear about how many people were lost to follow up in the study and/or had missing data, there was no meaningful comparison between those lost to follow up or with missing data in the study and the rest of the included sample)</li> <li>Evidence of bias from outcome measurement (for example, the paper is not clear about how the outcome was measured and what investigations were used, there appears to be no masking or confirmation with multiple readers, outcomes were taken from healthcare database codes where there is likely to be inconsistency in measurement or definition)</li> <li>Evidence of bias from study sample (for example, the paper is not clear about how many people were eligible for the study and were not included, there was no meaningful comparison between those included in the study and the population of interest for important differences)</li> <li>Evidence of bias from confounding factor measurement (for example, the paper is not clear about how the confounding factors were measured, it is not clear which confounders were adjusted for in analysis, not all the important confounders were adjusted for)</li> <li>Downgraded one level for non-significant effect</li> <li>Downgraded two levels for confidence interval crossing 2 lines of a defined minimal important difference</li> </ol>								

### Demographic and medical risk factors

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
Hypertension								
CAPT (2008) Prospective cohort	1,052	Serious <sup>1</sup>	N/A	Not serious	Not serious	HR (95% CI)	Suspected: 1.01 (0.76, 1.35) Definite: 1.98 (1.16, 3.39)	MODERATE
Age (50-59 years as reference category)								
CAPT	1,052	Serious <sup>1</sup>	N/A	Not serious	Not serious	HR (95% CI)	60-69 years:	MODERATE

© NICE 2018. All rights reserved. See [Notice of rights](#).

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
(2008) Prospective cohort							6.09 (1.72, 21.5) 70-79 years: 4.12 (1.18, 14.4) >79: 6.39 (1.64, 24.9)	
Age								
Klein (2007) Prospective cohort	3,917	Serious <sup>1,2</sup>	N/A	Not serious	Not serious	Time-adjusted odds ratios (95% CI)	Age (by increasing categories, 43-54 years, 55-64 years, 65-74 years, 75-86 years): 4.2 (2.9, 6.1)	MODERATE
Diabetes mellitus								
Hahn (2013) Retrospective cohort	6,621	Very Serious <sup>1,3,4,5</sup>	N/A	Not serious	Serious <sup>6</sup>	HR (95% CI)	1.03 (0.97, 1.09)	VERY LOW
Long term use of aspirin								
Klein (2012) Prospective cohort	4,926	Not serious	N/A	Not serious	Serious <sup>6</sup>	HR (95% CI)	Regular aspirin use: 1.65 (0.91, 2.99)	MODERATE
Smoking								
Klein (2008) Prospective cohort	2,119	Serious <sup>1,2</sup>	N/A	Not serious	Very Serious <sup>7</sup>	Time-adjusted odds ratios (95% CI)	Past vs never smokers: 0.88 (0.41, 1.88) Current vs never smokers: 0.18 (0.02, 1.40)	VERY LOW

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
History of MI								
Klein (2013) Prospective cohort	1,700	Serious <sup>2</sup>	N/A	Not serious	Very Serious <sup>7</sup>	Time-adjusted odds ratios (95% CI)	0.61 (0.07, 5.34)	VERY LOW
History of CVD								
Klein (2013) Prospective cohort	1,700	Serious <sup>2</sup>	N/A	Not serious	Very Serious <sup>7</sup>	Time-adjusted odds ratios (95% CI)	1.31 (0.32, 5.27)	VERY LOW
History of angina								
Klein (2013) Prospective cohort	1,700	Serious <sup>2</sup>	N/A	Not serious	Very Serious <sup>7</sup>	Time-adjusted odds ratios (95% CI)	1.53 (0.30, 7.85)	VERY LOW
Exercise (sedentary as reference group)								
Knudtson (2006) Prospective cohort	3,684	Very Serious <sup>1,2,3</sup>	N/A	Not serious	Very Serious <sup>7</sup>	Time-adjusted odds ratios (95% CI)	Active: 1.1 (0.5, 2.3)	VERY LOW
<ol style="list-style-type: none"> <li>1. Evidence of bias from study attrition (for example, the paper is not clear about how many people were lost to follow up in the study and/or had missing data, there was no meaningful comparison between those lost to follow up or with missing data in the study and the rest of the included sample)</li> <li>2. Evidence of bias from study sample (for example, the paper is not clear about how many people were eligible for the study and were not included, there was no meaningful comparison between those included in the study and the population of interest for important differences)</li> <li>3. Evidence of bias from prognostic factor measurement (for example, the paper is not clear about how the factor was measured, factors that require definition (e.g. hypertension) were not defined, arbitrary or questionable cut off points were used for continuous values)</li> <li>4. Evidence of bias from outcome measurement (for example, the paper is not clear about how the outcome was measured and what investigations were used, there appears to be no masking or confirmation with multiple readers, outcomes were taken from healthcare database codes where there is likely to be inconsistency in measurement or definition)</li> <li>5. Evidence of bias from confounding factor measurement (for example, the paper is not clear about how the confounding factors were measured, it is not</li> </ol>								

© NICE 2018. All rights reserved. See [Notice of rights](#).

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
clear which confounders were adjusted for in analysis, not all the important confounders were adjusted for)								
6. Downgraded one level for non-significant effect								
7. Downgraded two levels for confidence interval crossing 2 lines of a defined minimal important difference								

### Diet and nutrition

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
Daily Alcohol consumption, g (0 as reference category)								
Boekhorst (2008) Prospective cohort	4,229	Serious <sup>1,2</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	≤10: 1.10 (0.32, 3.80) >10 to ≤20: 1.38 (0.31, 6.16) >20: 3.27 (0.88, 12.19)	LOW
Total Fat, g (quintile 1 as reference category)								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 1.14 (0.82, 1.59) Quintile 3: 0.99 (0.70, 1.39) Quintile 4: 1.54 (1.13, 2.11) Quintile 5: 1.18 (0.85, 1.64)	VERY LOW
Saturated Fat, g (quintile 1 as reference category)								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 1.09 (0.78, 1.51) Quintile 3: 1.42 (1.03, 1.95) Quintile 4: 	VERY LOW



Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
							1.18 (0.85, 1.64) Quintile 5: 1.19 (0.87, 1.64)	
Monounsaturated Fat g (quintile 1 as reference category)								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Not serious	HR (95% CI)	Quintile 2: 1.37 (0.98, 1.91) Quintile 3: 1.22 (0.86, 1.71) Quintile 4: 1.38 (0.99, 1.94) Quintile 5: 1.47 (1.05, 2.05)	LOW
Total Polyunsaturated Fatty Acids g (quintile 1 as reference category)								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 0.95 (0.68, 1.33) Quintile 3: 1.10 (0.80, 1.52) Quintile 4: 1.34 (0.97, 1.85) Quintile 5: 1.13 (0.82, 1.55)	VERY LOW
Omega-3 fatty acids, Eicosapentaenoic Acid (EPA) - quintile 1 as reference category								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 0.92 (0.65, 1.30) Quintile 3: 1.16 (0.86, 1.58) Quintile 4: 1.00 (0.71, 1.39)	VERY LOW

© NICE 2018. All rights reserved. See [Notice of rights](#).

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
							Quintile 5: 0.84 (0.59, 1.18)	
Omega-3 fatty acids, Docosahexaenoic Acid (DHA) (g) - quintile 1 as reference category								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 0.99 (0.73, 1.36) Quintile 3: 1.14 (0.84, 1.53) Quintile 4: 0.93 (0.68, 1.27) Quintile 5: 0.72 (0.52, 1.01)	VERY LOW
Omega-3 fatty acids, DHA + EPA (g) - quintile 1 as reference category								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 0.98 (0.70, 1.38) Quintile 3: 1.20 (0.88, 1.64) Quintile 4: 0.91 (0.64, 1.29) Quintile 5: 0.79 (0.55, 1.12)	VERY LOW
Omega-3 fatty acids, Linolenic Acid (g) - quintile 1 as reference category								
Reynolds (2013)	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 0.90 (0.64, 1.23) Quintile 3: 1.02 (0.74, 1.42) Quintile 4: 1.06 (0.77, 1.47) Quintile 5:	VERY LOW

© NICE 2018. All rights reserved. See [Notice of rights](#).

Macular Degeneration  
Appendix H: Grade tables and meta-analysis results

Studies	Sample size	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect measure	Effect size	Quality
							1.08(0.80, 1.46)	
Omega-6 Fatty Acids, linoleic acid (g) - quintile 1 as reference category								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 0.98 (0.70, 1.37) Quintile 3: 1.04 (0.75, 1.44) Quintile 4: 1.36 (0.99, 1.87) Quintile 5: 1.11 (0.81, 1.53)	VERY LOW
Omega-6 Fatty Acids, Arachidonic Acid (g) - quintile 1 as reference category								
Reynolds (2013) Prospective cohort	4,165	Very serious <sup>1,2,3</sup>	N/A	Not serious	Serious <sup>4</sup>	HR (95% CI)	Quintile 2: 0.92 (0.67, 1.26) Quintile 3: 0.85 (0.62, 1.17) Quintile 4: 0.91 (0.66, 1.25) Quintile 5: 0.84 (0.62, 1.14)	VERY LOW
<ol style="list-style-type: none"> <li>1. Evidence of bias from study sample (for example, the paper is not clear about how many people were eligible for the study and were not included, there was no meaningful comparison between those included in the study and the population of interest for important differences)</li> <li>2. Evidence of bias from study attrition (for example, the paper is not clear about how many people were lost to follow up in the study and/or had missing data, there was no meaningful comparison between those lost to follow up or with missing data in the study and the rest of the included sample)</li> <li>3. Evidence of bias from prognostic factor measurement (for example, the paper is not clear about how the factor was measured, factors that require definition (e.g. hypertension) were not defined, arbitrary or questionable cut off points were used for continuous values)</li> <li>4. Downgraded one level for non-significant effect</li> </ol>								